Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 918 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: End of Life Clear all
Completed Phase 3 Interventional Results available

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life

NCT01160367
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, GI Cancer, Pancreatic Cancer
Interventions
TAILORED Patient Family Decision Making, standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting No phase listed Observational

Placental Risk Assessment to CusTomize Individualized Pregnancy Care and Evaluation

NCT07144839
View directory record Official record
Conditions
Stillbirth, Placental Insufficiency
Interventions
Data Collection Throughout Pregnancy and Delivery
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 50 Years · Female only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels' Perceptions of End-of-Life Care

NCT00760201
View directory record Official record
Conditions
End of Life Care
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
No. Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 23, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

NCT02541604
View directory record Official record
Conditions
Solid Tumor
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Active, not recruiting Phase 3 Interventional

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Results available

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT05216835
View directory record Official record
Conditions
Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions
Sabestomig (AZD7789)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 101 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Journeys to Wellness: A Transplant Candidate Study

NCT01254214
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
tMBSR, Support group
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jul 23, 2026, 4:20 PM EDT
Active, not recruiting Phase 2 Interventional

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

NCT05709574
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Tadalafil 20 MG
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Not applicable Interventional

The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals

NCT06087224
View directory record Official record
Conditions
Death; Neonatal, Morbidity;Newborn
Interventions
Teleneonatology
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
0 Days and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Anchorage, Alaska • Juneau, Alaska • Ketchikan, Alaska + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Terminated Not applicable Interventional

Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

NCT06543446
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
ICD implantation
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
3,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Portland, Maine • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed No phase listed Observational

Study of the Wearable Defibrillator in Heart-Failure Patients

NCT01326624
View directory record Official record
Conditions
Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
wearable defibrillator (LifeVest)
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Results available

Family Palliative and End-of-Life Care for Advanced Heart Failure

NCT04153890
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
FamPALcare
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

NCT04515810
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Refractory Hematologic Malignancy
Interventions
Internet-Based Intervention, Best Practice, Telephone-Based Intervention, Questionnaire Administration, Post-intervention qualitative feedback interview
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Manhasset, New York • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Results available

MK-3475/BCG in High Risk Superficial Bladder Cancer

NCT02324582
View directory record Official record
Conditions
Bladder Cancer
Interventions
Intravenous MK-3475/ Intravesical BCG
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Springfield, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 1 Interventional

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ZL-1310, Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
New York, New York • Memphis, Tennessee • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine Implantable Cardioverter-Defibrillator Trial

NCT01215253
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 23, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

NCT03115801
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Results available

Improving Goals of Care Discussion in Advanced Cancer Patients

NCT02374255
View directory record Official record
Conditions
Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions
GoC intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Enzalutamide, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Children's Books to Brochures for Safe Sleep and Infant Reading Education During Prenatal Care

NCT04031235
View directory record Official record
Conditions
Sudden Unexplained Infant Death, Child Rearing, Literacy
Interventions
Sleep Baby, Safe and Snug, Read Baby, Every Day
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Jul 23, 2026, 4:20 PM EDT